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Abstract 
Functionalised tetrahydrocarbazoles are accessed through an enantioselective 
organocatalysed Diels-Alder (D-A) reaction of 3-vinyl-1H-indole with a suitable dienophile in 
combination with an in situ N-protection. A subsequent diastereospecific ene reaction is then 
used to transfer chirality from the 10a to the 5 position with rearomatisation of the indolic 
ring, to give the target tetrahydrocarbazoles in high %ee. The in situ introduction of different 
N-protecting groups is explored along with their influence on the subsequent ene reactions. 
 
1. Introduction 
The carbazole scaffold is found in many bioactive molecules including both plant and 
microbial natural products and synthetic analogues.1,2 Examples include the staurosporine 
natural products, protein kinase inhibitors with potential applications in anti-cancer 
medicine.3 Molecules based on the related tetrahydrocarbazole core have been investigated 
for the treatment for neurological disorders such as Alzheimer’s disease,4 and include the 
drug ramatroban, currently used for the treatment of allergic rhinitis and asthma.5 The 
tetrahydrocarbazoles have also been shown to be useful intermediates for the synthesis of 
carbazoles via iodine mediated oxidation.6 A number of enantioselective routes to the 
tetrahydrocarbazoles have been reported, involving both transition-metal7 and organo-
catalyzed8 approaches. A recurring feature in synthetic approaches to both racemic9 and 
enantioenriched8(a,c,d,g,h,j-l) tetrahydrocarbazoles is the use a vinyl-indole, as a formal diene, in 
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a Diels-Alder (D-A) type reaction. The D-A reactions of vinyl-heteroaromatics have also been 
used extensively in the synthesis of natural products, such as the oroidin alkaloids,10 as well 
being employed in domino reactions for the construction of complex heterocycles.11 Recently 
we have reported our investigations into the D-A/ene reactions of a vinyl-heteroaromatics as 
a diastereoselective route to functionalised tetrahydrobenzoimidazoles and 
tetrahydrocarbazoles.12,13 Interested in the extension of this approach to the synthesis of 
enantioenriched tetrahydrocarbazoles, we decided to investigate the use of an 
enantioselective D-A reaction, of a vinyl-indole and dieneophile, followed by a stereospecific 
ene reaction to provide an overall enantioselective route to our target tetrahydrocarbazoles. 
An examination of the literature suggested that the organocatalyzed D-A reactions of 3-vinyl-
1H-indoles developed by Ricci et al.8a,k would be an ideal route to enantioenriched D-A 
cycloadducts which would in turn, given a suitable N-protecting group, undergo 
stereospecific ene reactions with concurrent rearomatisation of the indole (Scheme 1). 
 
Scheme 1: Previous enantioselective D-A reactions of vinyl-indoles and our planned 
enantioselective D-A/stereospecific ene route to enantioenriched tetrahydrocarbazoles. 
 
2. Results and discussion 
Prior to examining the planned enantioselective D-A/ene reaction sequence we decided to 
probe the conversion of racemic D-A cycloadducts 5 into tetrahydrocarbazoles 6 to 
understand the requirements for N-protection. We anticipated that electron donating N-
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protecting groups (e.g. Bn, Me) would accelerate the undesirable acid catalysed 
rearomatisation of D-A cycloadducts 5 to the detriment of the desired ene reaction pathway, 
whist overly electron withdrawing N-protecting groups would render the D-A cycloadducts 5 
unreactive towards ene chemistry. Thus a careful balancing of the electronic properties of 
the N-protecting group would be required. In the organocatalyzed D-A reaction of 3-vinyl-1H-
indole 1 with maleimides it is proposed that hydrogen bonding of the Soós catalyst 3 to the 
indolic NH of 1 is required to achieve a high enantiomeric excess in the product. Therefore 
our first challenge was the introduction of an N-protecting group, after the organocatalyzed 
D-A step, which would allow for a subsequent ene chemistry but before the unprotected D-A 
cycloadducts 4 can undergo rearromatisation. 
3-Vinyl-1H-indole (1) was therefore prepared according to a literature procedure14 and then 
reacted with N-methylmaleimide (2, NMM) at 70 oC for 2 hours in DCM to give the racemic 
D-A cycloadduct 4. Next we carried out an in situ N-protection with trifluoroacetic anhydride 
(TFAA) to give 5a in good yield. However unsurprisingly 5a proved very unreactive towards 
enophiles, such as nitrosobenzene. We therefore moved to investigate the introduction of 
alternative N-protecting groups, tert-butyloxycarbonyl (BOC), acetyl and tosyl, which we 
anticipated would be compatible with our planned ene chemistry (Table 1). 
 
Table 1: Synthesis of racemic 5(a-d) via a D-A/N-protection reaction. 
 
 Protecting Group (P) Reaction Conditions 
Yieldsa 
5 7 
1 Trifluoroacetyl TFAA, r.t., 1 h 91%, 5a - 
2 BOC (BOC)2O, NEt3, r.t., 18 h 40%, 5b 26% 
3 BOC (BOC)2O, NEt3, 20 mol% DMAP, r.t., 18 h 57%, 5b 8% 
4 Ac Ac2O, NEt3, 20 mol% DMAP, r.t., 18 h 55%, 5c 6% 
5 Ts TsCl, NEt3, r.t., 18 h 0%, 5d 76% 
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6 Ts Ts2O, NEt3, r.t., 20 h 70%, 5d - 
[a] Isolated yields. 
 
Racemic D-A cycloadduct 4 was generated as above followed by an in situ reaction with di-
tert-butyl dicarbonate and triethylamine to give BOC protected 5b in a modest yield of 40% 
along with 26% of rearomatised indole 7. However the yield 5b was improved to 57% and 
the formation of 7 supressed through the addition of catalytic DMAP in the protection step, 
presumably through an improved rate of protection verses that of rearomatisation. Acetyl 
protected 5c was prepared similarly from the in situ reaction of 4 with acetic anhydride in 
55% yield. Initial attempts to form tosyl protected 5d through trapping of 4 with p-
toluenesulfonyl chloride in the presence of triethylamine gave only indole 7, however good 
yields of 5d could be obtained through the use of p-toluenesulfonic anhydride (Table 1).15 
With N-protected D-A cycloadduct adducts 5b-d in hand, we next investigated their ene 
reactions with a selection of nitroso, azo and carbonyl based enophiles (nitrosobenzene, 1-
methyl-2-nitrosobenzene, 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) and 2,3,4,5,6-
pentafluorobenzaldehyde). Reaction of BOC protected 5b with either nitrosobenzene or 
PTAD gave low yields of the ene products 8a-b alongside rearomatised indole 9a and 
carbazole 10a (likely arising from aerial oxidation of 9a or elimination/oxidation of 8a-b). 
Acetyl protected 5c gave ene adducts 8c-e with the best isolated yields ranging from 57 to 
75%, but during optimisation studies these reactions proved to be highly capricious and 
yields were difficult to replicate. However a single crystal of compound 8c was obtained 
through slow evaporation from chloroform, allowing confirmation of the relative 
stereochemistry by X-ray diffraction analysis (Figure 1, Table 4).16 
 
Figure 1: ORTEP representation of the X-ray crystal structure of 8c. 
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Finally tosyl protected compound 5d readily underwent ene reactions with nitroso enophiles 
and 2,3,4,5,6-pentafluorobenzaldehyde, catalysed by dimethylaluminum chloride, to give 
tetrahydrocarbazoles 8f-h cleanly and in good yields (Table 2).17 
Table 2: Ene reactions of racemic 5b-d. 
 
 
Starting 
Material 
Protecting 
Group (P) 
Enophile 
Reaction 
conditions 
R 
Yields/%a 
8 9 10 
1 5b BOC 
 
rt, 3 h N(o-Tol)OH 
37%, 
8a 
5%, 
9b 
14%, 
10b 
2 5b BOC 
 
0 oC, 4 h 
 
46%, 
8b 
9%, 
9b 
11%, 
10b 
3 5c Ac 
 
rt, 18 h N(Ph)OH 
64%, 
8c 
- - 
4 5c Ac 
 
rt, 18 h N(o-Tol)OH 
75%, 
8d 
- - 
5 5c Ac 
 
0 oC, 5 h 
 
57%, 
8e 
- - 
6b 5d Ts 
 
rt, 18 h N(Ph)OH 
68%, 
8f 
- - 
7b 5d Ts 
 
rt, 18 h N(o-Tol)OH 
72%, 
8g 
- - 
8b 5d Ts 
 
DMAC, 
-78 oC – rt, 
24 h 
CH(C6F5)OH 
73%, 
8h 
- - 
[a] Isolated yields. [b] Results from ref. 12b included for comparison. 
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We therefore chose to focus our efforts on the tosyl protected series and turned our attention 
to combining the organocatalyed D-A reactions of Ricci et al.8a,k with an ene reaction. Soos’s 
organocatalyst was synthesized according to the literature18 and employed in the D-A 
reaction between 3-vinyl-1H-indole 1 and NMM. After 48 hours at -55 oC, p-toluenesulfonic 
anhydride and triethylamine were added to the reaction, allowing isolation of the tosyl 
protected D-A cycloadduct (3aS,10aS,10bS)-5d  in high yield and %ee (Scheme 2). 
 
Scheme 2: Organocatalysed D-A / N-protection reaction to give D-A adduct 
(3aS,10aS,10bS)-5d. 
 
Isolated D-A cycloadduct (3aS,10aS,10bS)-5d could then be reacted under our optimised 
ene reaction conditions with nitrosobenzene, 1-methyl-2-nitrosobenzene or 2,3,4,5,6-
pentafluorobenzaldehyde. Due to the concerted nature of the ene reaction, the chirality at 
position 10a is transferred to position 5 during the reaction and the indole rearomatised to 
give our target tetrahydrocarbazoles (3S,5S,10bS)-8f-h as single enantiomers in high %ee 
(Table 3).19 
 
Table 3: Ene reactions of (3aS,10aS,10bS)-5d. 
 
 Enophile Reaction Conditions R Yielda eeb 
1 PhNO rt, 18 h N(Ph)OH 73%, (3S,5S,10bS)-8f >95% 
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2 o-TolNO rt, 18 h N(o-Tol)OH 70%, (3S,5S,10bS)-8g >95% 
3 C6F5CHO, 
DMAC, -78 oC 1 h, 
rt 18 h 
CH(C6F5)OH
c 70%, (3S,5S,10bS)-8h >95% 
[a] Isolated yields. [b] %ee measured by chiral HPLC. [c] the stereochemistry of the 5-((S)-
hydroxy(perfluorophenyl)methyl) group is a consequence of an endo-ene reaction, and was 
assigned through comparison to the relative stereochemistry (single crystal X-ray analysis) 
of a related compound (see ref 12b, compound 3v). 
 
3. Conclusions 
In conclusion we have demonstrated a practically straight-forward, two-step D-A / N-
protection, ene reaction sequence allowing access to complex tetrahydrocarbazoles with 
excellent enantiomeric control. Future work will compare the biological activity of 
enantioenriched tetrahydrocarbazoles to their racemic counterparts as well as extending the 
scope of this synthetic approach. 
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4. Experimental 
1H and 13C NMR spectra were recorded directly with a Jeol Lambda 500 MHz, Jeol ECS-400 
MHz or Bruker Avance 300 MHz. HRMS data were provided by the EPSRC National Mass 
Spectrometry Service (University of Swansea). X-ray diffraction data was obtained on an 
Oxford Diffraction Gemini. IR spectra were obtained as neat samples using a Varian 800 
FTIR Scimitar Series spectrometer scanning from 4000-600 cm-1. Melting points were 
obtained using a Stuart SMP3 melting point machine. HPLC analysis was performed using a 
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Varian Prostar equipped with a PDA detector. Specific rotations were measured using an 
Optical Activity PolAAr 2001. THF was distilled from sodium/benzophenone and used 
directly. DCM was distilled from calcium hydride and used directly. 
5a – (3aS*,10aS*,10bS*)-2-methyl-10-(2,2,2-trifluoroacetyl)-4,10,10a,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione 
Into a Schlenk flask was added, 3-vinyl-1H-indole (200 mg, 1.40 mmol), 1-methyl-1H-
pyrrole-2,5- dione (155 mg, 1.40 mmol) and DCM (5 mL). The solution was stirred at 70 oC 
for 2 hours before the reaction was cooled to room temperature and trifluoroacetic anhydride 
(1.47 mL, 7.0 mmol) was added. The solution was stirred at room temperature for 1 hour 
before the solution was poured into water and extracted with DCM (3 x 10 mL). The 
combined organic extracts were dried with MgSO4, filtered and the solvent was removed 
under reduced pressure to leave the crude product as a yellow oil. The crude product was 
purified using column chromatography (Petrol: Ethyl acetate 1: 1, column diameter = 2 cm, 
silica = 14 cm) to give (3aS*,10aS*,10bS*)-2-methyl-10-(2,2,2-trifluoroacetyl)-4,10,10a,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (91%, 452 mg, 1.27 mmol) as an off 
white solid. 
Mp: 214 – 216 oC. Rf: 0.20 (Pet:EA, 3:1). 
1H NMR (300 MHz, CDCl3) δH 8.32 (d, J = 8.4 Hz, 
0.5H), 7.44 – 7.35 (1.5H, m), 7.32 – 7.20 (1H, m), 7.15 – 7.02 (1H, m), 6.17 (1H, dd, J = 6.9, 
3.5 Hz), 5.02 – 4.89 (1H, m), 4.30 (0.5H, app t, J = 8.1 Hz), 3.80 (0.5H, app t, J = 8.1 Hz), 
3.19 (1H, app t, J = 7.6 Hz), 3.09 – 2.97 (1H, m), 2.71 (3H, s), 2.29 – 2.15 (1H, m). 13C NMR 
(75 MHz, CDCl3) δC 178.8, 178.3, 174.7, 173.9, 144.9, 140.9, 137.1, 135.2, 130.5, 130.2, 
127.7, 126.5, 126.0, 125.4, 121.3, 120.3, 119.1, 115.0, 114.1, 113.5, 111.2, 77.5, 77.3, 77.1, 
76.6, 61.4, 59.7, 42.0, 39.0, 38.2, 37.8, 25.1 25.1, 24.9. IR(neat): υmax/cm
-1 3010, 2941, 
1652. MS (pNSI): 351.1 (100%, (M+H)+), 373.1 (68%, (M+Na)+), 723.2 (8%, (2M+Na)+). 
HRMS (pNSI): calcd for C17H14F3N2O3 [M+H]
+: 351.0951; observed: 351.0954. 
5b - tert-butyl (3aS*,10aS*,10bS*)-2-methyl-1,3-dioxo-2,3,3a,4,10a,10b-
hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate 
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In a boiling tube, 3-vinyl-1H-indole (100 mg, 0.70 mmol) was dissolved in DCM (3 mL). Into 
the stirred solution, N-methylmaleimide (78 mg, 0.70 mmol) was added and the sealed tube 
was heated at 70 oC for 2 hours. The solution was cooled to room temperature and di-tert-
butyl dicarbonate (0.64 mL, 2.8 mmol), triethylamine (0.39 mL, 2.8 mmol) and DMAP (17 
mg, 0.14 mmol) were added to the reaction. The reaction was stirred room temperature for 
18 hours before the solution was poured into water (20 mL), and extracted with DCM (2 x 15 
mL). The combined organic extracts were dried over MgSO4, filtered and the solvent was 
removed under reduced pressure to leave the crude product as an orange oil. The crude 
product was purified by column chromatography (Petrol: Diethyl ether: DCM 2: 1: 1), column 
diameter = 2 cm, silica = 19 cm) to give tert-butyl (3aS*,10aS*,10bS*)-2-methyl-1,3-dioxo-
2,3,3a,4,10a,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (57%, 142 mg, 0.4 
mmol) as a yellow powder. 
Mp: 97 - 100 oC. Rf: 0.39 (Pet:Et2O:DCM, 2:1:1). 
1H NMR (300 MHz, CDCl3) δH 6.14 (1H, dd, 
J = 7.5, 3.7 Hz), 4.74 (0.6H, app dt, J = 7.6, 3.1 Hz), 4.66 (0.4H, app dt, J = 7.8, 3.0 Hz), 
4.33 (0.6H, app t, J = 8.2 Hz), 4.04 (0.4H, t, J = 8.4 Hz), 3.22 – 3.02 (2H, m), 2.80 (1.4H, s), 
2.79 (1.6H, s), 2.27 – 2.14 (1H, m), 1.70 (5H, s), 1.64 (4H, s). 13C NMR (75 MHz, CDCl3) δC 
178.9, 174.6, 137.8, 130.0, 125.9, 122.3, 120.4, 120.2, 115.9, 115.7, 111.8, 82.1, 59.5, 41.0, 
37.8, 28.5, 24.9, 24.7. IR(neat): υmax/cm
-1 2975, 2930, 1695. MS (pNSI): 255.1 (100%, (M-
(Boc)+H)+), 299.1 (47%, (M-(C(Me3))+H)
+), 355.2 (20%, (M+H)+), 372.2 (57%, (M+(NH4)
+)), 
726.4 (5%, (2M+(NH4))
+). HRMS (pNSI): calcd for C20H26N3O4 [M+NH4]
+: 372.1918; 
observed: 372.1919. 
5c - (3aS*,10aS*,10bS*)-10-acetyl-2-methyl-4,10,10a,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione 
In a boiling tube, 3-vinyl-1H-indole (0.20 g, 1.4 mmol) was dissolved in DCM (4 mL). Into the 
stirred solution, N-methylmaleimide (0.16 g, 1.4 mmol) was added and the sealed tube was 
heated at 70 oC for 2 hours. The solution was cooled to room temperature and acetic 
anhydride (0.66 mL, 7.0 mmol), triethylamine (0.78 mL, 5.6 mmol) and DMAP (34 mg, 0.28 
mmol) was added to the reaction. The reaction was stirred at room temperature for 18 hours 
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before the solution was poured into a solution of sodium bicarbonate (30 mL) and extracted 
with DCM (2 x 10 mL). The combined organic layers were dried over MgSO4, filtered and the 
solvent removed under reduced pressure to leave the crude product as a pale orange yellow 
solid. The crude product was purified by column chromatography (Petrol: Ethyl Acetate 3: 1 
(300 mL) Petrol : Ethyl Acetate 1 : 1 (200 mL), column diameter = 2 cm, silica = 18 cm) to 
give (3aS*,10aS*,10bS*)-10-acetyl-2-methyl-4,10,10a,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione (55%, 0.23 g, 0.77 mmol) as a white powder. 
Mp: 187 - 189 oC. Rf: 0.10 (Pet:EA, 1:1). 
1H NMR (400 MHz, CDCl3) δH 7.40 (1H, d, J = 7.6 
Hz), 7.27 – 7.22 (2H, m), 7.02 – 6.98 (1H, m), 6.13 (1H, app dt, J = 7.3, 3.6 Hz), 4.86 (1H, 
dd, J = 6.7, 3.3 Hz), 4.37 (1H, app t, J = 7.9 Hz), 3.17 (1H, t, J = 7.9 Hz), 3.03 (1H, app dd, J 
= 14.3, 7.4 Hz), 2.73 (3H, s), 2.57 (3H, s), 2.21 (1H, app ddq, J = 14.3, 6.8, 3.4 Hz). 13C 
NMR (101 MHz, CDCl3) δC 179.3, 175.4, 169.0, 144.0, 136.9, 130.0, 127.4, 123.2, 121.5, 
114.3, 112.7, 112.7, 59.8, 40.1, 38.0, 25.8, 25.2, 25.0. IR(neat): υmax/cm
-1 3051, 2930, 1696; 
MS (pNSI): 297.1 (100%, (M+H)+), 615.2 (10%, (2M+Na)+). HRMS (pNSI): calcd for 
C17H17N2O3 [M+H]
+: 297.1234; observed: 297.1237. 
5d - (3aS*,10aS*,10bS*)-2-methyl-10-tosyl-4,10,10a,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione 
Racemic synthesis - In a boiling tube, 3-vinyl-1H-indole (0.2 g, 1.4 mmol) and DCM (7 mL) 
was added. To the stirred solution, N-methylmaleimide (0.16 g, 1.4 mmol) was added and 
the sealed tube was heated at 70 oC for 3 hours. The solution was cooled to room 
temperature and triethylamine (0.48 mL, 3.5 mmol) and p-toluenesulfonic anhydride (0.64 g, 
1.96 mmol) were added to the reaction. The reaction was stirred at room temperature for 18 
hours before the solution was poured into water (20 mL) and extracted with DCM (2 x 10 
mL). The combined organic layers were dried over MgSO4, filtered and the solvent removed 
under reduced pressure to leave the crude product as an orange oil. The product was 
purified by column chromatography (Petrol: Ethyl acetate, 4: 1, column diameter = 2 cm, 
silica = 15 cm) to give (3aS*,10aS*,10bS*)-2-methyl-10-tosyl-4,10,10a,10b-
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tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (70%, 0.405 g, 0.98 mmol) as a white 
powder. 
(3aS,10aS,10bS)-5d - (3aS,10aS,10bS)-2-methyl-10-tosyl-4,10,10a,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione 
Enantioselective synthesis - Into a Schlenk flask was added NMM (17 mg, 0.15 mmol), 1-
(3,5-bis(trifluoromethyl)phenyl)-3-((1R)-(6-methoxyquinolin-4-yl)((2R,4R,5S)-5-
vinylquinuclidin-2-yl)methyl)thiourea (18 mg, 20 mol%) and DCM (1 mL), The solution was 
cooled to -55 oC before a pre-cooled solution of 3-vinyl-1H-indole (25 mg, 0.18 mmol) in 
DCM (0.5 mL) was added. The solution was stirred at -55 oC for 48 h before a solution of p-
toluenesulfonic anhydride (245 mg, 0.75 mmol) in DCM (1.5 mL) was added. The solution 
was warmed to room temperature and stirred for 20 hours. The solution was poured into 
NaHCO3 and extracted with DCM (3 x 5 mL). The combined organic extracts were dried over 
MgSO4, filtered and the solvent removed under reduced pressure to leave the crude product 
as an orange oil. The product was purified by column chromatography (Petrol: DCM: Et2O, 
2: 1: 1, column diameter = 1 cm, silica = 14 cm) to give (3aS,10aS,10bS)-2-methyl-10-tosyl-
4,10,10a,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (74%, 45 mg, 0.11 mmol) 
as a white solid.  
Mp: 204.2 – 208.0 oC (racemic); Rf: 0.09 (Pet:EA, 1:1); 
1H NMR (300 MHz, CDCl3) δH 7.72 
(2H, d, J = 8.0 Hz), 7.61 (1H, d, J = 8.5 Hz), 7.21 – 7.19 (2H, d, J = 8.0), 7.21-7.16 (1H, m), 
6.92 (1H, app t, J = 7.5 Hz), 6.01 – 5.96 (1H, m), 4.47 (1H, dd, J = 7.0, 3.3 Hz), 3.99 (1H, 
app t, J = 8.1 Hz), 3.12 (1H, app t, J = 8.1 Hz), 2.99-2.92 (1H, m), 2.76 (3H, s), 2.30 (3H, s), 
2.11 (1H, ddd, J = 18.0, 6.4, 2.4 Hz); 13C NMR (400 MHz, CDCl3) δC 178.9, 174.2, 144.7, 
144.6, 137.4, 134.3, 130.4, 129.9, 127.5, 126.4, 123.9, 121.0, 115.4, 112.9, 61.6, 43.3, 37.2, 
25.3, 25.1, 21.7; IR(neat): υmax/cm
-1 2981, 2889, 1694; MS (pNSI): 409.2 (61%, (M+H)+), 
426.1 (100%, (M+(NH4))
+), 834.3 (52%, (2M+(NH4))
+); HRMS (pNSI): calcd C22H21N2O4S 
[M+H]+: 409.1217; observed: 409.1218. The ee of the product was determined by HPLC 
using an AD-H column (n-hexane/iPrOH 80:20, flow rate 0.75 mL/min, tmaj = 35.1 min, tmin = 
77.2 min, >95% ee). [α]D
25 = +180 (c = 0.16 in CHCl3). 
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8a – tert-butyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-2-methyl-1,3-dioxo-
2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate 
To a stirred Schlenk flask was added tert-butyl (3aS*,10aS*,10bS*)-2-methyl-1,3-dioxo-
2,3,3a,4,10a,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (100 mg, 0.28 
mmol), 2-methyl-1-nitrosobenzene (34 mg, 0.17 mmol) and DCM (4 mL). The solution was 
stirred at room temperature for 3 hours. The solvent was removed under reduced pressure 
to leave the crude product as a yellow solid. The crude product was purified by column 
chromatography (Petrol: Diethyl ether: DCM 2: 1: 1,  column diameter = 1 cm, silica = 16 cm) 
to give tert-butyl (3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-2-methyl-1,3-dioxo-
2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (37%, 49 mg, 0.10 
mmol) as an off white powder.  
Mp: 157.9 - 159.6 oC; Rf: 0.50 (Pet:Et2O:DCM, 2:1:1); 
1H NMR (400 MHz, CDCl3) δH 8.11 
(1H, d, J = 8.6 Hz), 7.66 (1H, d, J = 7.9 Hz), 7.57 (1H, d, J = 8.1 Hz), 7.30 – 7.24 (1H, m), 
7.21 (1H, app t, J = 7.7 Hz), 7.16 – 7.09 (2H, m), 7.05 (1H, app t, J = 7.4 Hz), 5.08 (1H, d, J 
= 8.1 Hz), 4.97 (1H, br s), 4.41 – 4.34 (1H, app t, J = 5.7 Hz), 3.67 (1H, app q, J = 7.4 Hz), 
2.91 (3H, s), 2.31 (3H, s), 2.59 (1H, app dt, J = 12.9, 6.2 Hz), 1.98 (1H, ddd, J = 12.9, 7.6, 
4.6 Hz), 1.73 (9H, s); 13C NMR (101 MHz, CDCl3) δC 178.6, 174.5, 150.3, 149.2, 137.0, 
131.1, 130.0, 129.8, 127.6, 126.5, 125.2, 124.7, 122.9, 121.5, 120.0, 117.6, 115.3, 84.7, 
57.4, 40.3, 39.1, 28.2, 25.2, 23.9, 18.6; IR(neat): υmax/cm
-1 3474, 2981, 2929, 1696; MS 
(pNSI): 253.1 (100%, (M-((N(OH)Ph)(Boc))+H)+), 353.1 (72%, (M-(N(OH)2-Tol))+), 374.2 
(38%, (M-(Boc)+H)+), 458.2 (32%, (M-(H2O)+H)
+), 474.2 (62%, (M-H)+), 475.2 (18%, 
(M+H)+), 498.2 (30%, (M+Na)+),  973.4 (15%, 2M+Na)+); HRMS (pNSI): calcd for C27H30N3O5 
[M+H]+: 476.2180; observed: 476.2173. 
8b – tert-butyl (3aS*,5S*,10bS*)-5-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-2-methyl-
1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate 
To a stirred Schlenk flask was added tert-butyl (3aS*,10aS*,10bS*)-2-methyl-1,3-dioxo-
2,3,3a,4,10a,10b-hexahydropyrrolo[3,4-a]carbazole-10(1H)-carboxylate (57 mg, 0.16 mmol) 
and DCM (3 mL). The solution was cooled to 0 oC before 4-phenyl-3H-1,2,4-triazole-3,5(4H)-
13 
 
dione (35 mg, 0.20 mmol) was added. The solution was stirred at 0 oC for 4 hours before the 
solvent was removed under reduced pressure to leave the crude product as an orange oil. 
The crude product was purified by column chromatography (Petrol: Diethyl ether: DCM 2: 1: 
1,  column diameter = 1 cm, silica = 14 cm) to give tert-butyl (3aS*,5S*,10bS*)-5-(3,5-dioxo-
4-phenyl-1,2,4-triazolidin-1-yl)-2-methyl-1,3-dioxo-2,3,3a,4,5,10b-hexahydropyrrolo[3,4-
a]carbazole-10(1H)-carboxylate (46%, 39 mg, 0.07 mmol) as a yellow powder. 
Mp: 142.5 – 144.7 oC; Rf: 0.06 (Pet:Et2O:DCM, 2:1:1); 
1H NMR (400 MHz, CDCl3) δH 8.08 
(1H, d, J = 8.4 Hz), 7.52 (1H, d, J = 7.7 Hz), 7.43 (4H, app dt, J = 13.0, 7.3 Hz), 7.38 – 7.28 
(2H, m), 7.21 (1H, app t, J = 7.5 Hz), 5.55 (1H, app t, J = 5.3 Hz), 5.07 (1H, d, J = 8.0 Hz), 
3.61 – 3.55 (1H, m), 2.92 (3H, s), 2.45 (1H, dt, J = 13.8, 5.7 Hz), 2.24 (1H, ddd, J = 14.1, 
8.9, 4.3 Hz), 1.68 (9H, s); 13C NMR (101 MHz, CD2Cl2) δC 177.6, 173.6, 153.7, 152.5, 150.0, 
131.0, 130.8, 129.3, 128.4, 126.1, 126.0, 125.5, 125.4, 123.5, 118.8, 115.7, 113.2, 85.3, 
47.9, 39.9, 38.4, 28.2, 27.4, 25.3; IR(neat): υmax/cm
-1 3251, 3075, 2942, 1691; MS (pNSI): 
253.1 (100%, (M-((PTAD)(Boc))+H)+), 474.1 (29%, (M-(C(Me)3+H)
+), 530.2 (30%, (M+H)+), 
547.2 (100%, (M+NH4)
+), 1076.4 (14%, (2M+(NH4)
+); HRMS (pNSI): calcd for C28H28N5O6 
[M+H]+: 530.2034; observed: 530.2031. 
8c – (3aS*,5S*,10bS*)-10-acetyl-5-(hydroxy(phenyl)amino)-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione 
To a stirred Schlenk flask was added (3aS*,10aS*,10bS*)-10-acetyl-2-methyl-4,10,10a,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (60 mg, 0.20 mmol), nitrosobenzene 
(22 mg, 0.20 mmol) and DCM (3 mL). The solution was stirred at room temperature for 18 
hours. The solvent was removed under reduced pressure to leave the crude product as a 
pale red solid. The crude product was purified by column chromatography (Petrol: Diethyl 
ether 2: 1,  column diameter = 1 cm, silica = 16 cm) to give (3aS*,5S*,10bS*)-10-acetyl-5-
(hydroxy(phenyl)amino)-2-methyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-
dione (64%, 52 mg, 0.13 mmol) as an off white powder. 
Mp: 88.7 - 90.3 oC; Rf: 0.06 (Pet:Et2O, 2:1); 
1H NMR (400 MHz, CDCl3) δH 7.81 – 7.64 (1H, 
m), 7.37 – 7.25 (4H, m), 7.25 – 7.12 (3H, m), 7.04 – 7.00 (1H, m), 5.61 (1H, br s), 5.03 – 
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4.99 (1H, m), 4.80 – 4.75 (1H, m), 3.54 – 3.42 (1H, m), 2.80 (6H, s), 2.39 – 2.30 (1H, s), 2.01 
– 1.92 (1H, m); 13C NMR (101 MHz, CD2Cl2) δC 178.4, 174.7, 171.1, 151.0, 136.5, 130.6, 
129.0, 128.0, 124.8, 123.0, 122.3, 120.5, 118.7, 117.1, 114.1, 57.8, 39.9, 39.2, 27.3, 24.9, 
22.6; IR(neat): υmax/cm
-1 3359, 2956, 2859, 1695; MS (pNSI): 295.1 (34%, (M-(N(OH)Ph))+), 
426.1 (100%, (M+Na)+), 807.3 (16%, (2M+H)+), 829.3 (36%, (2M+Na)+); HRMS (pNSI): calcd 
for C23H21N3O4Na [M+Na]
+: 426.1424; observed: 426.1424. 
8d – (3aS*,5S*,10bS*)-10-acetyl-5-(hydroxy(o-tolyl)amino)-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione 
To a stirred Schlenk flask was added (3aS*,10aS*,10bS*)-10-acetyl-2-methyl-4,10,10a,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (60 mg, 0.20 mmol), 2-methyl-1-
nitrosobenzene (25 mg, 0.20 mmol) and DCM (3 mL). The solution was stirred at room 
temperature for 18 hours. The solvent was removed under reduced pressure to leave the 
crude product as a pale yellow solid. The crude product was purified by column 
chromatography (Petrol: Ethyl Acetate 3: 1,  column diameter = 1 cm, silica = 14 cm) to give 
(3aS*,5S*,10bS*)-10-acetyl-5-(hydroxy(o-tolyl)amino)-2-methyl-4,5,10,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (75%, 63 mg, 0.15 mmol) as a pale 
yellow powder. 
Mp: 104.7 - 106.5 oC; Rf: 0.50 (Pet:EA, 1:1); 
1H NMR (400 MHz, CDCl3) δH  7.68 (1H, d, J = 
8.4 Hz), 7.57 (1H, d, J = 8.1 Hz), 7.54 (1H, d, J = 7.7 Hz), 7.27 (1H, d, J = 7.7 Hz), 7.20 (1H, 
app td, J = 8.1, 7.5, 2.1 Hz), 7.11 (1H, app t, J = 7.6 Hz), 7.08 – 7.01 (2H, m), 5.28 (1H, br 
s), 5.18 (1H, d, J = 8.1 Hz), 4.38 (1H, dd, J = 6.0, 4.5 Hz), 3.70 (1H, app td, J = 8.3, 5.6 Hz), 
2.65 (1H, app dt, J = 13.5, 6.0 Hz), 2.25 (3H, s), 1.88 (1H, ddd, J = 13.5, 8.3, 4.5 Hz); 13C 
NMR (101 MHz, CD2Cl2) δC 178.7, 174.8, 171.3, 149.5, 136.0, 130.9, 130.9, 130.1, 128.2, 
126.6, 125.3, 124.6, 122.9, 121.7, 120.6, 118.1, 113.6, 57.5, 40.2, 38.9, 29.8, 27.4, 25.1; 
IR(neat): υmax/cm
-1 3379, 3008, 2922, 1691; MS (pNSI): 295.1 (21%, (M-(N(OH)o-Tol))+), 
440.2 (100%, (M+Na)+), 857.3 (16%, (2M+Na)+); HRMS (pNSI): calcd for C24H23N3O4Na 
[M+Na]+: 440.1581; observed: 440.1581. 
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8e – (3aS*,5S*,10bS*)-10-acetyl-5-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-2-methyl-
4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione 
To a stirred Schlenk flask was added (3aS*,10aS*,10bS*)-10-acetyl-2-methyl-4,10,10a,10b-
tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (60 mg, 0.20 mmol) and DCM (3 mL). 
The solution was cooled to 0 oC before 4-phenyl-3H-1,2,4-triazole-3,5(4H)-dione (35 mg, 
0.20 mmol) was added. The solution was stirred at 0 oC for 5 hour before the solvent was 
removed under reduced pressure to leave the crude product as an orange oil. The crude 
product was purified by column chromatography (Petrol: Ethyl Acetate 1: 1,  column 
diameter = 1 cm, silica = 15 cm) to give (3aS*,5S*,10bS*)-10-acetyl-5-(3,5-dioxo-4-phenyl-
1,2,4-triazolidin-1-yl)-2-methyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-
dione (57%, 54 mg, 0.11 mmol) as an orange powder. 
Mp: 238.4 - 240.1 oC; Rf: 0.07 (Pet:EA, 1:1); 
1H NMR (400 MHz, CDCl3) δH 8.80 (1H, br s), 
7.62 (1H, d, J = 8.4 Hz), 7.54 (1H, d, J = 7.7 Hz), 7.46 – 7.41 (2H, m), 7.41 – 7.36 (2H, m), 
7.33 – 7.28 (2H, m), 7.29 – 7.24 (1H, m), 5.57 (1H, app t, J = 4.8 Hz), 5.07 (1H, d, J = 7.9 
Hz), 3.62 – 3.49 (1H, m), 2.88 (3H, s), 2.69 (3H, s), 2.53 – 2.43 (1H, m), 2.09 (1H, ddd, J = 
14.7, 10.4, 5.4 Hz); 13C NMR (101 MHz, CD2Cl2) δC 177.6, 173.9, 154.5, 153.6, 152.1, 136.2, 
131.6, 131.0, 129.3, 128.5, 126.7, 125.7, 125.6, 125.4, 123.5, 119.4, 113.9, 47.2, 39.9, 38.3, 
28.0, 27.1, 25.2; IR(neat): υmax/cm
-1 3255, 3080, 2932, 1693; MS (pNSI): 295.1 (44%, (M-
(PTAD)+), 472.2 (100%, (M+H)+), 489.2 (81%, (M+(NH4))
+), 960.3 (35%, (2M+(NH4)
+)); 
HRMS (pNSI): calcd for C25H22N5O5 [M+H]
+: 472.1615; observed: 472.1606. 
(3S,5S,10bS)-8f – (3aS,5S,10bS)-5-(hydroxy(phenyl)amino)-2-methyl-10-tosyl-
4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione  
To a stirred round bottomed flask was added (3aS,10aS,10bS)-2-methyl-10-tosyl-
4,10,10a,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (100 mg, 0.24 mmol), 
DCM (5 mL) and nitrosobenzene (26 mg, 0.24 mmol). The resulting solution was stirred at 
room temperature for 18 hours. The solvent was removed under reduced pressure to leave 
the crude product as a pale yellow solid which was purified by column chromatography 
(Petrol: Ethyl acetate 3:1, column diameter = 2 cm, silica = 15 cm) to give (3aS,5S,10bS)-5-
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(hydroxy(phenyl)amino)-2-methyl-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-
1,3(2H,3aH)-dione (73%, 85 mg, 0.16 mmol) as a yellow powder. 
Rf: 0.64 (Pet:EA, 1:1); 
1H NMR (500 MHz, CD2Cl2): δH 7.94 (1H, d, J = 8.4 Hz), 7.69 (2H, d, J 
= 8.2 Hz), 7.60 (1H, d, J = 7.9 Hz), 7.32 - 7.25 (3H, m) , 7.23 (2H, d, J = 8.2 Hz), 7.18-7.13 
(3H, m), 7.02 (1H, t, J = 7.3 Hz), 5.06 (1H, d, J = 8.0 Hz), 4.75 (1H, app t, J = 5.9 Hz), 4.72 
(1H, s), 3.64 (1H, app q, J = 7.2 Hz), 2.95 (3H, s), 2.43 (1H, app dt, J = 13.6, 6.4 Hz), 2.35 
(3H, s), 2.06 (1H, ddd, J = 13.6, 7.2, 4.9); 13C NMR (101 MHz, CD2Cl2): δC 178.1, 173.6, 
150.7, 145.3, 137.5, 134.9, 131.4, 129.7, 128.9, 128.9, 126.8, 125.2, 124.2, 122.6, 121.7, 
120.2, 117.2, 115.4, 58.0, 40.5, 39.5, 25.0, 23.3, 21.4; IR(neat): υmax/cm
-1 3661, 2990, 2886, 
1690; MS (pNSI): 407.1 (66%, (M-(C6H5NOH))
+), 516.2 (49%, (M+H)+), 533.2 (100%, 
(M+NH4)
+), 1031.3 (57%, (2M+H)+), 1053.3 (13%, (2M+Na)+); HRMS (pNSI): calcd for  
C28H26N3O5S [M+H]
+: 516.1588; observed: 516.1584. 
Note: 1H NMR run at 35 oC, broad signals observed at room temperature. 
The ee of the product was determined by HPLC using an AD-H column (n-hexane/iPrOH 
80:20, flow rate 0.75 mL/min, tmaj = 23.4 min, tmin = 56.1 min, >95% ee). [α]D
25 = +42 (c = 
0.50 in CHCl3). 
(3S,5S,10bS)-8g – (3aS,5S,10bS)-5-(hydroxy(o-tolyl)amino)-2-methyl-10-tosyl-
4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione  
To a stirred round bottomed flask was added (3aS,10aS,10bS)-2-methyl-10-tosyl-
4,10,10a,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (50 mg, 0.12 mmol), 
DCM (5 mL) and 1-methyl-2-nitrosobenzene (16 mg, 0.12 mmol). The resulting solution was 
stirred at room temperature for 18 hours. The solvent was removed under reduced pressure 
to leave the crude product as a pale yellow solid. The product was purified by column 
chromatography (Petrol: Ethyl acetate 4:1, column diameter = 1.5 cm, silica = 14 cm) to give 
(3aS,5S,10bS)-5-(hydroxy(o-tolyl)amino)-2-methyl-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione (70%, 46 mg, 0.09 mmol) as a yellow powder. 
Rf: 0.59 (Pet:EA 1:1); 
1H NMR (400 MHz, CD2Cl2): δH 7.89 (1H, d, J = 8.3 Hz), 7.65 (2H, d, J 
= 8.4 Hz), 7.40 (1H, d, J = 7.9 Hz), 7.28 (1H, d, J = 7.7 Hz) 7.21-7.18 (3H, m), 7.13-6.99 (4H, 
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m), 5.04 (1H, d, J = 8.1 Hz), 4.87 (1H, s), 4.27 (1H, app. t, J = 5.4 Hz), 3.73 (1H, app td, J = 
8.0, 6.1 Hz), 2.91 (3H, s), 2.58 (1H, app dt, J = 12.9, 6.2 Hz), 2.32 (3H, s), 2.25 (3H, s), 1.95 
(1H, ddd, J = 12.9, 7.8, 4.5 Hz); 13C NMR (101 MHz, CD2Cl2): δC 178.2, 173.6, 149.3, 145.3, 
137.3, 134.9, 131.6, 130.9, 129.7, 129.7, 129.2, 126.8, 126.2, 125.0, 124.9, 124.1, 121.4, 
120.5, 115.3, 57.3, 40.6, 39.4, 25.0, 24.6, 21.4, 18.3; IR(neat): υmax/cm
-1 3662, 2990, 2886, 
1701; MS (pNSI): 407.1 (98%, (M-((o-CH3)-C6H4NOH))
+), 530.2 (52%, (M+H)+), 547.2 (65%, 
(M+NH4)
+), 1059.3 (100%, (2M+H)+); HRMS (pNSI): calcd for C29H28N3O5S [M+H]
+: 
530.1744; observed: 530.1743. The ee of the product was determined by HPLC using an 
AD-H column (n-hexane/iPrOH 80:20, flow rate 0.75 mL/min, tmaj = 17.8 min, tmin = 22.8 min, 
>95% ee). [α]D
25 = +44 (c = 0.50 in CHCl3). 
(3aS,5S,10bS)-8h – (3aS,5S,10bS)-5-((S)-hydroxy(perfluorophenyl)methyl)-2-methyl-10-
tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione   
To a stirred round bottomed flask was added (3aS,10aS,10bS)-2-methyl-10-tosyl-
4,10,10a,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione (100 mg, 0.34 mmol) 
DCM (5 mL) and 1-methyl-1H-pyrrole-2,5-dione (38 mg, 0.34 mmol) and the resulting 
solution was heated at reflux for 48 hours. The reaction was cooled to -78 oC and 2,3,4,5,6-
pentafluorobenzaldehyde (0.04 mL, 0.34 mmol) was added followed by DMAC (1M in 
hexane, 0.34 mL, 0.34 mmol). The reaction was stirred at -78 oC for 60 minutes before being 
allowed to warm to room temperature. The reaction was stirred at room temperature for 24 
hours. The reaction was poured into saturated sodium bicarbonate solution (10 mL) and 
extracted with DCM (2 x 10mL). The combined organic layers were dried with MgSO4, 
filtered and the solvent was removed under reduced pressure to give the crude product as a 
pale brown solid. The product was purified by column chromatography (Petrol: Ethyl acetate 
3 : 1, column diameter = 2 cm, silica = 15 cm) to give (3aS,5S,10bS)-5-((S)-
hydroxy(perfluorophenyl)methyl)-2-methyl-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-
a]carbazole-1,3(2H,3aH)-dione (70 %, 149 mg, 0.25 mmol). 
Rf: 0.24 (Pet:EA 3:1); 
1H NMR (300 MHz, CDCl3): δH δ 7.85 (3H, app d, J = 8.4 Hz), 7.31 – 
7.22 (4H, m), 7.22 – 7.14 (1H, m), 5.13 (1H, d, J = 8.1 Hz), 4.99 (1H, d, J = 7.5 Hz), 3.71 – 
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3.52 (2H, m), 3.01 (3H, s), 2.38 (3H, s), 2.20 – 2.10 (1H, m), 1.67 (1H, app td, J = 13.8, 5.3 
Hz); 13C NMR (101 MHz, CDCl3): δC 177.7, 173.3, 145.3, 137.4, 135.4, 129.8, 129.7, 129.6, 
127.2, 125.3, 123.9, 120.1, 119.9, 115.2, 70.2, 41.5, 39.1, 36.9, 28.7, 25.2, 21.7; IR(neat): 
υmax/cm
-1 3371, 2981, 2889, 1690;MS (pNSI): 605.1 (40%, (M+H)+), 622.1 (88%, (M+NH4)
+), 
627.1 (100%, (M+Na)+), 643.1 (17%), 709.1 (15%); HRMS (pNSI): calcd for 
C29H21F5N2NaO5S [M+Na]
+: 627.0984; observed: 627.0968. Note: 13C NMR missing peaks 
due to C-F coupling.  The ee of the product was determined by HPLC using an AD-H column 
(n-hexane/iPrOH 80:20, flow rate 0.75 mL/min, tmaj = 16.4 min, tmin = 17.9 min, >95% ee). 
[α]D
25 = +56 (c = 0.60 in CHCl3). 
Table 4. Crystal data and structure refinement for 8c 
Empirical formula C23H21N3O4 
Formula weight 403.43 
Temperature/K 150.0 
Crystal system triclinic 
Space group P-1 
a/Å 8.1162(8) 
b/Å 10.6439(8) 
c/Å 12.9645(8) 
α/° 112.463(7) 
β/° 94.175(7) 
γ/° 104.046(8) 
Volume/Å3 986.79(15) 
Z 2 
ρcalcg/cm
3 1.358 
μ/mm-1 0.095 
F(000) 424.0 
Crystal size/mm3 0.3 × 0.1 × 0.1 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.742 to 50.7 
Index ranges -9 ≤ h ≤ 9, -11 ≤ k ≤ 12, -15 ≤ l ≤ 15 
Reflections collected 7561 
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Independent reflections 3587 [Rint = 0.0344, Rsigma = 0.0566] 
Data/restraints/parameters 3587/0/278 
Goodness-of-fit on F2 1.015 
Final R indexes [I>=2σ (I)] R1 = 0.0452, wR2 = 0.0901 
Final R indexes [all data] R1 = 0.0676, wR2 = 0.1015 
Largest diff. peak/hole / e Å-3 0.27/-0.22 
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